黄嘌呤氧化还原酶抑制剂研究进展

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (10): 1081-1086.

• 综述 • 下一篇

黄嘌呤氧化还原酶抑制剂研究进展

朱深银^1,2, 周远大¹, 杜冠华²

¹重庆医科大学附一院临床药理研究室, 重庆 400016;
²中国医学科学院药物研究所, 北京 100050

收稿日期:2006-02-25 修回日期:2006-05-12 出版日期:2006-10-26 发布日期:2020-11-05
通讯作者: 杜冠华, 男, 博士, 教授, 博士生导师, 研究方向:新药发现和评价, 神经药理学。Tel:010-63165184 E-mail:dugh@imm.ac.cn
作者简介:朱深银, 男, 在读博士, 讲师, 主要从事新药发现和评价。Tel:010-63131571 　E-mai l:zhushenyin0486@sina.com
基金资助:
国家“863”重大专项资助项目(No2004AA273782)

Research progress of xanthine oxidoreductase in biological functions and its inhibitor development

ZHU Shen-yin^1,2, ZHOU Yuan-da¹, DU Guan-hua²

¹Department of Clinical Pharmacology , the First Affiliated Hospital of Chongqing University of Medical Science,Chongqing 400016 , China;
²Institute of Materia Medica , Chinese Academy of Medical Science , Beijing 100050 , China

Received:2006-02-25 Revised:2006-05-12 Online:2006-10-26 Published:2020-11-05

摘要/Abstract

摘要： 黄嘌呤氧化还原酶为钼蛋白酶家族成员, 最被人们所知的生物学功能是催化嘌呤分解代谢, 生成尿酸并伴随大量活性氧产生, 与痛风发生密切相关。近年研究发现其还参与其他物质代谢, 同时与缺血再灌注损伤、心血管疾病尤其与心衰密切相关, 而其抑制剂对这些疾病具有较好的治疗作用, 因而针对此靶点的药物研发又受到广泛关注。

关键词: 黄嘌呤氧化还原酶, 活性氧, 缺血再灌注, 心衰, 药物开发

Abstract: xanthine oxidoreductase(XOR)is a member of the molybdoenzyme family and best known for its catalytic role in purine degradation , metabolizing hypoxanthine and xanthine to uric acid with concomitant generation of superoxide and hydrogen peroxide.In addition to its role in the pathophysiology of hyperuricaemia and gout , the role for XOR beyond purine metabolism was first suggested in ischaemia-reperfusion injury , there is growing evidence that it also participates in endothelial dysfunction,hypertension and heart failure.Importantly , the XOR inhibitor attenuates dysfunction especially in heart failure caused by XOR in these disease states.Attention to the broader range of XOR bioactivity in the cardiovascular system has prompted strong interest based XOR drug development by pharmaceuticals company.

Key words: xanthine oxidoreductase, reactive oxygen species, ischaemia-reperfusion injury, heart failure, drug development

中图分类号:

朱深银, 周远大, 杜冠华. 黄嘌呤氧化还原酶抑制剂研究进展[J]. 中国临床药理学与治疗学, 2006, 11(10): 1081-1086.

ZHU Shen-yin, ZHOU Yuan-da, DU Guan-hua. Research progress of xanthine oxidoreductase in biological functions and its inhibitor development[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(10): 1081-1086.

参考文献

1 Harrison R.Structure and function of xanthine oxidoreductase:where are we now[J] ?Free Radic BiolMed, 2002;33:774-97
2 Berry CE, Hare JM.Xanthine oxidoreductase and cardiovascular disease:molecular mechanisms and pathophysiological implications[J].J Physiol, 2004;555:589-606
3 Xu P, Huecksteadt TP, Hoidal JR.Molecular cloning and characterization of the human xanthine dehydrogenase gene (XDH)[J].Genomics, 1996;34:173-80
4 McManaman JL, Bain DL.Structural and conformational analysis of the oxidase to dehydrogenase conversion of xanthine oxidoreductase[J].J Biol Chem , 2002;277:21261-8
5 Maia L, Vala A, Mira L.NADH oxidase activity of rat liver xanthine dehydrogenase and xanthine oxidase-contribution for damage mechanisms[J].Free Radic Res, 2005;39:979-86
6 Li H, Samouilov A, Liu X, Zweier JL.Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction:evaluation of its role in nitrite and nitric oxide generation in anoxic tissues[J].Biochemistry , 2003;42:1150-9
7 Millar TM.Peroxynitrite formation from the simultaneous reduction of nitrite and oxygen by xanthine oxidase[J].FEBS Lett,2004;562:129-33
8 Pritsos CA.Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system[J].Chem Biol Interact,2000;129:195-208
9 Nishino T, Okamoto K, Kawaguchi Y, Hori H, Matsumura T,Eger BT, et al.Mechanism of the conversion of xanthine dehydrogenase to xanthine oxidase:identification of the two cysteine disulfide bonds and crystal structure of a non-convertible Chin J Clin Pharmacol Ther 2006 Oct;11(10) rat liver xanthine dehydrogenase mutant[J].J Biol Chem ,2005;280:24888-94
10 Angelos MG, Kutala VK, Torres CA, He G, Stoner JD, Mohammad M, et al.Hypoxic reperfusion of the ischemic heart and oxygen radical generation[J].Am J Physiol Heart Circ Physiol, 2006;290:H341-7
11 Choi HK, Mount DB, Reginato AM.Pathogenesis of gout[J].Ann InternMed, 2005;143:499-516
12 Zalba G, Beaumont J, San Jose G, Fortuno A, Fortuno MA,Diez J.Vascular oxidant stress:molecular mechanisms and pathophysiological implications[J].J Physiol Biochem , 2000;56:57-64
13 Houston M, Estevez A, Chumley P, Aslan M, Marklund S,Parks DA, et al.Binding of xanthine oxidase to vascular endothelium.Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling[J].J Biol Chem, 1999;274:4985-94
14 Patetsios P, Song M, Shutze WP, Pappas C, Rodino W,Ramirez JA, et al.Identification of uric acid and xanthine oxidase in atherosclerotic plaque[J].Am J Cardiol, 2001;88:188-91
15 Laakso J, Mervaala E, Himberg JJ, Teravainen TL, Karppanen H, Vapaatalo H, et al.Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension[J].Hypertension,1998;32:902-6
16 Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C,Mu W, et al.Hyperuricemia induces endothelial dy sfunction[J].Kidney Int , 2005;67:1739-42
17 Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R,Kohler C, et al.vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure:role of xanthineoxidase and extracellular superoxide dismutase[J].Circulation ,2002;106:3073-8
18 de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, et al.Enhanced expression and activity of xanthine oxidoreductase in the failing heart[J].J Mol Cell Cardiol, 2000;32:2083-9
19 Mellin V, Isabelle M, Oudot A, Vergely-Vandriesse C,Monteil C, Di Meglio B, et al.Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure[J].Eur Heart J ,2005;26:1544-50
20 Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, et al.Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart[J].Circ Res, 2002;90:297-304
21 Kinugasa Y, Ogino K, Furuse Y, Shiomi T, Tsutsui H,Yamamoto T, et al.Allopurinol improves cardiac dy sfunction after ischemia-reperfusion via reduction of oxidative stress in isolated perfused rat hearts[J].Circ J , 2003;67:781-7
22 GuanW, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, et al.Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction[J].J Cardiovasc Pharmacol, 2003 , 41:699-705
23 Kogler H, Fraser H, McCune S, Altschuld R, Marban E.Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium[J].Cardiovasc Res, 2003;59:582-92
24 Amado LC, Saliaris AP, Raju SV, Lehrke S, St John M, Xie J, et al.Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure[J].JMol Cell Cardiol, 2005;39:531-6
25 Duncan JG, Ravi R, Stull LB, Murphy AM.Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy[J].Am J Physiol Heart Circ Physiol , 2005;289:H1512-8
26 Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD.Allopurinol improves endothelial dysfunction in chronic heart failure[J].Circulation, 2002;106:221-6
27 Kittleson MM, Hare JM.Xanthine oxidase inhibitors:an emerging class of drugs for heart failure[J].Eur Heart J, 2005;26:1458-60
28 Freudenberger RS, Schwarz RPJr, Brown J, Moore A, Mann D, GivertzMM, et al.Rationale , design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure[J].Expert Opin Investig Drugs , 2004;13:1509-16
29 Becker MA, Schumacher HR, Wortmann RL, MacDonald PA,Palo WA, Eustace D, et al.Febuxostat , a novel nonpurine selective inhibitor of xanthine oxidase:a twenty-eight-day , multicenter , phase II , randomized, double-blind, placebo-controlled,dose-response clinical trial examining safety and efficacy in patients with gout[J].Arthritis Rheum , 2005;52:916-23
30 Zhu JX, Wang Y, Kong LD, Yang C, Zhang X.Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver[J].J Ethnopharmacol, 2004;93:133-40
31 Yu Z, Fong WP, Cheng CH.The dual actions of morin (3 , 5,7, 2', 4'-pentahydroxyflavone)as a hypouricemic agent:uricosuric effect and xanthine oxidase inhibitory activity[J].J Pharmacol ExPTher , 2006;316:169-75
32 Wang Y, Zhu JX, Kong LD, Yang C, Cheng CH, Zhang X.Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase oxidase activities in oxonate-treated mice[J].Basic Clin Pharmacol Toxicol, 2004;94:232-7
33 Yoshizumi K, Nishioka N, Tsuji T.Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats[J].Yakugaku Zasshi, 2005;125:315-21
34 Kong LD, Cai Y, Huang WW, Cheng CH, Tan RX.Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout[J].J Ethnopharmacol , 2000;73:199-207

[1]	缪亚东, 李蹊, 王燕, 高坡, 周敏, 于浩. 抗肿瘤药物临床试验数据管理的一般考虑[J]. 中国临床药理学与治疗学, 2022, 27(9): 1055-1060.
[2]	王亚丽, 霍续磊, 陈峰, 李生兰, 郑晓红, 王灿, 李文斌. 硝呋莫司抗肿瘤作用的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 955-960.
[3]	李雯霞, 方柳圆, 钱申贤. 铁死亡的机制及其在淋巴瘤中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(3): 314-321.
[4]	李莹, 姚伟, 王萌, 余志宏, 龚园其, 蓝海兵, 齐协飞. 鸢尾素通过NF-κB和JNK信号通路减轻屋尘螨诱导的气道上皮细胞炎症及凋亡的实验研究[J]. 中国临床药理学与治疗学, 2022, 27(10): 1106-1112.
[5]	李健，闫方，杨进波，王玉珠. 从纳武利尤单抗用法用量变更看模型引导的药物开发方法在剂量优化中的应用[J]. 中国临床药理学与治疗学, 2020, 25(4): 408-412.
[6]	李健，杨进波，王玉珠. 模型引导的药物开发在新药研发中的应用[J]. 中国临床药理学与治疗学, 2020, 25(1): 1-8.
[7]	严洁萍，章水均，张国兵，胡颖，罗丹，江红娟，李敏静. 丁苯酞对S-亚硝基化谷胱甘肽诱导脑微血管内皮细胞损伤的保护作用及机制研究[J]. 中国临床药理学与治疗学, 2019, 24(5): 517-522.
[8]	刘若海，卢园园，李丽伶，沈露露，曹红，李军，李旭. D-4F在七氟烷处理对急性高糖血症小鼠血管保护中的作用及机制[J]. 中国临床药理学与治疗学, 2017, 22(7): 743-748.
[9]	商宏恺，傅爱萍，陈露芳，仝进毅，斯奇. 地塞米松对人胎盘葡萄糖转运功能的作用及机制[J]. 中国临床药理学与治疗学, 2017, 22(11): 1221-1226.
[10]	李少华, 伊力哈木江·克尤木, 徐琦, 邵培培, 程路峰. 依普利酮对慢性心力衰竭患者CD4⁺T淋巴细胞Kv1.3等通道mRNA及蛋白表达的抑制作用[J]. 中国临床药理学与治疗学, 2017, 22(11): 1259-1264.
[11]	苏丽，王锃，黄菲，蓝瑞隆，石丹，陈纯，张鲁榕，张纬建，洪金省. 甘草次酸减轻放射性炎症反应的作用机制研究[J]. 中国临床药理学与治疗学, 2016, 21(10): 1088-1094.
[12]	张雪, 谢海棠, 吴兰香, 沈杰, 周宏灏. 异硫氰酸苯乙酯通过上调ROS激活p53诱导MCF-7细胞凋亡机制的研究[J]. 中国临床药理学与治疗学, 2015, 20(7): 754-758.
[13]	唐若愚, 屈莺歌, 许洪涛, 阎澜, 颜天华, 姜远英, 曹永兵. 红景天苷防治急性高原病的作用及机制[J]. 中国临床药理学与治疗学, 2015, 20(7): 822-827.
[14]	杨国栋, 张晓英, 冯志松, 贺国斌, 江毅敏. N-异喹啉-3-羧酸-L-亮氨酸苄酯抗人食道癌作用的研究[J]. 中国临床药理学与治疗学, 2014, 19(8): 877-881.
[15]	赵春梅, 王安才, 王德国. 骨髓干细胞治疗心脏疾病的临床新进展[J]. 中国临床药理学与治疗学, 2014, 19(8): 948-952.

黄嘌呤氧化还原酶抑制剂研究进展

Research progress of xanthine oxidoreductase in biological functions and its inhibitor development

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价